Zyversa Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
OQB
ZyVersa Therapeutics, Inc.'s Chief Commercial Officer, Karen A. Cashmere, was granted 48,100 stock options with an exercise price of $0.59, vesting over three years, though the Form 4 filing was delayed due to an administrative oversight.
OQB
ZyVersa Therapeutics, Inc. Director Gregory Gene Freitag was granted 11,066 stock options with an exercise price of $0.59, vesting over three years.
OQB
ZyVersa Therapeutics, Inc. CEO Stephen C. Glover was granted 136,900 stock options with an exercise price of $0.59, vesting over three years.
OQB
ZyVersa Therapeutics Director Robert G. Finizio was granted 11,066 stock options with an exercise price of $0.59, vesting over three years.
OQB
Peter Wolfe, Chief Financial Officer of ZyVersa Therapeutics, Inc., was granted 60,100 stock options with an exercise price of $0.59 per share, vesting over three years.
OQB
ZyVersa Therapeutics, Inc. has granted its Chief Medical Officer, Pablo A. Guzman, 48,900 stock options with an exercise price of $0.59, vesting over three years.
OQB
ZyVersa Therapeutics, Inc. Director Min-Chul Park was granted 11,066 stock options with an exercise price of $0.59, vesting over three years.
OQB
ZyVersa Therapeutics, Inc. Director and 10% Owner James Sapirstein was granted 11,066 stock options with an exercise price of $0.59, vesting over three years.
OQB
Karen A. Cashmere, a director at ZyVersa Therapeutics, belatedly reports the acquisition of stock options, initially omitted due to an administrative oversight.
OQB
Peter Wolfe, CFO of ZyVersa Therapeutics, reports a previously unreported stock option grant received in May 2023.
OQB
ZyVersa Therapeutics CEO Stephen C. Glover was granted stock options and a previous reporting oversight was corrected via a Form 4 filing with the SEC.
OQB
Min-Chul Park, a director of ZyVersa Therapeutics, acquired stock options and amended a previous filing to correct an administrative oversight.
OQB
Gregory Freitag, a director at ZyVersa Therapeutics, received stock options and amended a previous filing to correct an administrative oversight.
OQB
James Sapirstein, a director at ZyVersa Therapeutics, disclosed a previously unreported stock option grant from May 2023 in a recent SEC filing.
OQB
Robert G. Finizio, a director of ZyVersa Therapeutics, reports the acquisition of stock options after accounting for two reverse stock splits.